These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 28763044)

  • 1. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
    Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
    Kubizek F; Eggenreich B; Spadiut O
    Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
    Yao H; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.
    Strop P; Liu SH; Dorywalska M; Delaria K; Dushin RG; Tran TT; Ho WH; Farias S; Casas MG; Abdiche Y; Zhou D; Chandrasekaran R; Samain C; Loo C; Rossi A; Rickert M; Krimm S; Wong T; Chin SM; Yu J; Dilley J; Chaparro-Riggers J; Filzen GF; O'Donnell CJ; Wang F; Myers JS; Pons J; Shelton DL; Rajpal A
    Chem Biol; 2013 Feb; 20(2):161-7. PubMed ID: 23438745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the construction of antibody-drug conjugates.
    Chudasama V; Maruani A; Caddick S
    Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates: Current status and future perspectives.
    Gébleux R; Casi G
    Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.